Chronic myeloid Leukaemia (CML) is a type of cancer that affects the blood and bone marrow. In CML the bone marrow produces too many white cells, called granulocytes. These cells, sometimes called blasts or leukaemic blasts, gradually crowd the bone marrow, interfering with normal blood cell production. Mer-418™ is a patent NCE that is used as first line and second line therapy for CML and is compared to Imatinib, Dasatinib and Nilotinib with superiority in many parameters. Mer-418™ molecule is an evidence based medicine with publications in the reliable American Society of Hematology.


  • Mer-418™ - Patent NCE
  • Merotinib™ 100, 200, 300 & 400mg
  • NCCN guidelines 2016
  • American Society of Hematology

Merotinib™ our Imatinib brand is the only product that meets National Comprehensive Cancer Network guidelines for Imatinib intolerant patients. Merotinib™ is the first to be launched as 300mg dosage. We also have the widest Merotinib™ range of 100mg, 200mg, 300mg & 400mg.